NCT05221229View on ClinicalTrials.gov

Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )

Active, not recruitingOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

April 17, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 1, 2026

Conditions
Atrial FibrillationRecurrenceOverweight and ObesityLiraglutide
Interventions
DRUG

Liraglutide plus upstream risk factors modification advice and consultation

Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.

Trial Locations (1)

B15 2GW

University Hospitals Birmingham NHS Foundation Trust, Birmingham

All Listed Sponsors
collaborator

University of Birmingham

OTHER

lead

University Hospital Birmingham

OTHER

NCT05221229 - Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF ) | Biotech Hunter | Biotech Hunter